Page 44 - Read Online
P. 44

David et al. Hepatoma Res 2018;4:2  I  http://dx.doi.org/10.20517/2394-5079.2017.51                                                    Page 5 of 8


               Table 2. Pathologic findings in patients according to treatment group
                                                     OLR (n = 21)           LLR (n = 28)          p
               Greatest tumor size (cm; mean ± SD)   5.3 ± 2.6               4.4 ± 1.7          0.048
               Tumor number                          2.0 ± 1.2               1.5 ± 0.7          0.074
               Margin distance (cm; mean ± SD)       1.7 ± 2.4               1.4 ± 1.5          0.649
               ES tumor grade (I/II/III/IV)          0:8:12:1:0              1:12:10:4:1        0.425
               pT stage                                                                         0.031
                 T1                                  2                       9
                 T2                                  9                       15
                 T3                                  9                       2
                 T4                                  1                       1
               Cirrhosis present                     9 (42.9%)               19 (67.9%)         0.080
               Microvascular invasion                10 (47.6%)              12 (42.9%)         0.740
               LLR: laparoscopic liver resection; OLR: open liver resection; ES: Edmondson-Steiner. Values are expressed as mean ± standard deviation or
               number (percent).


               Table 3. Complications according to treatment group
                                                     OLR (n = 21)          LLR (n = 28)          p
                Intraoperative                        3 (14.3%)             5 (17.9%)            0.738
                Postoperative                         7 (33.3%)             4 (14.3%)            0.114
                Clavien-Dindo classification                                                     0.256
                  Grade I                             2                     0
                  Grade II                            0                     0
                  Grade IIIa                          3                     3
                  Grade IIIb                          2                     1
                  Grade IVa/IVb                       0                     0
                Postoperative serious complications   5 (23.8%)             4 (14.3%)            0.237
                (Clavien-Dindo Grade III or higher)
                Hospital stay (days; mean ± SD: range)  20.6 ± 30.1 (7-147)  9.2 ± 4.9 (4-30)    0.023
               LLR: laparoscopic liver resection; OLR: open liver resection

               significant difference in terms of DFS between the groups (P = 0.947). The 1-, 3- and 5-year DFS was 59.3%,
               20.2% and 16.2% for the LLR group and 51.0%, 44.6% and 37.2% for OLR groups, respectively [Figure 1].


               DISCUSSION
                                                                                                    [8]
               HCC is widely endemic, with 80% of new cases worldwide expected to develop in Asia alone . The
               management of HCC is complex, due to the presence of two disease processes: the primary malignancy
               and the underlying liver pathology that accompanies HCC. Thus a reliable management algorithm to guide
               therapeutic decisions in these patients is needed.

               Currently, the BCLC classification system is one of the most widely recognized and approved staging
               systems for HCC, since it considers multiple factors such as tumor stage and function, patient’s performance
                                                    [9]
               status, as well as cancer-related symptoms . According to BCLC, intermediate stage (BCLC-B) patients
               are asymptomatic (PS score 0), with large multi-nodular tumors but without macrovascular invasion or
                               [8]
               extrahepatic spread . The estimated 3-year survival for patients with untreated stage B HCC ranges from 8%
               to 50%; given the invasiveness of surgery, palliation with TACE is therefore recommended for these subset of
                      [9]
               patients . However, TACE cannot induce complete tumor necrosis especially in large tumors, with reported
               response rates in literature as low as 2% [8,10] .

               Liver resection, based on the BCLC system, is usually reserved for patients with small, single tumors, with
                                                              [9]
               absence of portal hypertension or hyperbilirubinemia . Recent data has however, supported the benefit
               of surgical resection in terms of short- and long-term oncologic outcomes despite the presence of large,
                                                                                          [11]
                                                          [4]
               multinodular nodules and macrovascular invasion . In a recent study done by Kim et al. , overall median
   39   40   41   42   43   44   45   46   47   48   49